Supplementary Figure S3 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
<p>Extended Data relating to Main Figure 3/AKT-driven progression of ALDH1A1+ cells in glioblastoma. A, Flow cytometry histograms showing ALDH1A1 expression in the paired treatment-naive vs. clinical relapse patient samples quantified in main Fig. 3A. Isotype controls in gray. B, Flow cytometr...
-д хадгалсан:
| Үндсэн зохиолч: | |
|---|---|
| Бусад зохиолчид: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Хэвлэсэн: |
2025
|
| Нөхцлүүд: | |
| Шошгууд: |
Шошго нэмэх
Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!
|
| _version_ | 1849927634134237184 |
|---|---|
| author | Sied Kebir (15048732) |
| author2 | Vivien Ullrich (15048735) Pia Berger (15048738) Celia Dobersalske (15048741) Sarah Langer (15048744) Laurèl Rauschenbach (15048747) Daniel Trageser (15048750) Andreas Till (15048753) Franziska K. Lorbeer (15048756) Anja Wieland (15048759) Timo Wilhelm-Buchstab (15048762) Ashar Ahmad (15048765) Holger Fröhlich (8724576) Igor Cima (15048768) Shruthi Prasad (15048771) Johann Matschke (15048774) Verena Jendrossek (15048777) Marc Remke (14962619) Barbara M. Grüner (14947089) Alexander Roesch (15048780) Jens T. Siveke (11780911) Christel Herold-Mende (15047946) Tobias Blau (15048783) Kathy Keyvani (15048786) Frank K.H. van Landeghem (15048789) Torsten Pietsch (15048792) Jörg Felsberg (15048795) Guido Reifenberger (12335398) Michael Weller (15037908) Ulrich Sure (15048798) Oliver Brüstle (15048801) Matthias Simon (15048804) Martin Glas (15048807) Björn Scheffler (15048810) |
| author2_role | author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author |
| author_facet | Sied Kebir (15048732) Vivien Ullrich (15048735) Pia Berger (15048738) Celia Dobersalske (15048741) Sarah Langer (15048744) Laurèl Rauschenbach (15048747) Daniel Trageser (15048750) Andreas Till (15048753) Franziska K. Lorbeer (15048756) Anja Wieland (15048759) Timo Wilhelm-Buchstab (15048762) Ashar Ahmad (15048765) Holger Fröhlich (8724576) Igor Cima (15048768) Shruthi Prasad (15048771) Johann Matschke (15048774) Verena Jendrossek (15048777) Marc Remke (14962619) Barbara M. Grüner (14947089) Alexander Roesch (15048780) Jens T. Siveke (11780911) Christel Herold-Mende (15047946) Tobias Blau (15048783) Kathy Keyvani (15048786) Frank K.H. van Landeghem (15048789) Torsten Pietsch (15048792) Jörg Felsberg (15048795) Guido Reifenberger (12335398) Michael Weller (15037908) Ulrich Sure (15048798) Oliver Brüstle (15048801) Matthias Simon (15048804) Martin Glas (15048807) Björn Scheffler (15048810) |
| author_role | author |
| dc.creator.none.fl_str_mv | Sied Kebir (15048732) Vivien Ullrich (15048735) Pia Berger (15048738) Celia Dobersalske (15048741) Sarah Langer (15048744) Laurèl Rauschenbach (15048747) Daniel Trageser (15048750) Andreas Till (15048753) Franziska K. Lorbeer (15048756) Anja Wieland (15048759) Timo Wilhelm-Buchstab (15048762) Ashar Ahmad (15048765) Holger Fröhlich (8724576) Igor Cima (15048768) Shruthi Prasad (15048771) Johann Matschke (15048774) Verena Jendrossek (15048777) Marc Remke (14962619) Barbara M. Grüner (14947089) Alexander Roesch (15048780) Jens T. Siveke (11780911) Christel Herold-Mende (15047946) Tobias Blau (15048783) Kathy Keyvani (15048786) Frank K.H. van Landeghem (15048789) Torsten Pietsch (15048792) Jörg Felsberg (15048795) Guido Reifenberger (12335398) Michael Weller (15037908) Ulrich Sure (15048798) Oliver Brüstle (15048801) Matthias Simon (15048804) Martin Glas (15048807) Björn Scheffler (15048810) |
| dc.date.none.fl_str_mv | 2025-11-25T12:46:36Z |
| dc.identifier.none.fl_str_mv | 10.1158/1078-0432.30706281 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/figure/Supplementary_Figure_S3_from_A_Sequential_Targeting_Strategy_Interrupts_AKT-Driven_Subclone-Mediated_Progression_in_Glioblastoma/30706281 |
| dc.rights.none.fl_str_mv | CC BY info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Cancer Therapeutic Research and Development Clinical Research and Trials CNS Cancers Gliomas, Glioblastomas Drug Targets Precision Medicine |
| dc.title.none.fl_str_mv | Supplementary Figure S3 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma |
| dc.type.none.fl_str_mv | Image Figure info:eu-repo/semantics/publishedVersion image |
| description | <p>Extended Data relating to Main Figure 3/AKT-driven progression of ALDH1A1+ cells in glioblastoma. A, Flow cytometry histograms showing ALDH1A1 expression in the paired treatment-naive vs. clinical relapse patient samples quantified in main Fig. 3A. Isotype controls in gray. B, Flow cytometry histograms of ALDH1A1 derived from treatment-naive and paired experimental relapse (TMZ→eR) BN46 cells. Data quantification in Supplementary Fig. S2B. C, Cartoon illustrating course of neurosphere experiments, quantified in main Fig. 3B and in Supplementary Fig. S3D, applying treatment-naive and paired experimental and clinical relapse patient cells. Right: Exemplary qRT-PCR data presenting knockdown efficacy of the siRNA approach in respective cells, normalized to siNT control. Mean of duplicates ± SD. D, Source data for Fig. 3B, and for Supplementary Fig. S3E. Dotplots show percent neurosphere-forming cells estimated from neurospheres at 12 days after seeding. Paired patient cell analysis, evaluating 1° and 2° neurospheres of indicated knockdown (siALDH1A1) and respective control (siNT) cell samples. Data shown as mean ± SD. E, Neurosphere assay, similar to main Fig. 3B on paired treatment-naive vs. experimental relapse (TMZ→eR) BN46 cells. Source data in Supplementary Fig. S3D. Data as mean ± SD. F, Protein patterns, similar to Fig. 3D. on paired cells from 2 additional discovery cohort samples. G, Flow cytometry histograms depicting pAKT(Ser473) expression in the paired treatment-naive vs. clinical relapse patient samples quantified in main Fig. 3E. Isotype controls in gray. H, Flow cytometry histograms of pAKT(Ser473) and, right, quantification of data derived from treatment-naive and paired experimental relapse (TMZ→eR) BN46 cells. Data represent mean fluorescence intensities (MFI), ± SD, normalized to isotype control (gray). I, Representative source data for Fig. 3F. Flow cytometry profiles of ALDH1A1/pAKT(Ser473)-labeled, paired treatment-naive vs. clinical relapse cell samples. J, Flow cytometry profiles of of ALDH1A1/pAKT(Ser473)-labeled, paired treatment-naive vs. experimental relapse conditions of BN46 cells (in vitro exposure to TMZ (TMZ→eR) or irradiation (RT→eR)).</p> |
| eu_rights_str_mv | openAccess |
| id | Manara_d582048a4a8e2ee52cb46ba66799090a |
| identifier_str_mv | 10.1158/1078-0432.30706281 |
| network_acronym_str | Manara |
| network_name_str | ManaraRepo |
| oai_identifier_str | oai:figshare.com:article/30706281 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY |
| spelling | Supplementary Figure S3 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in GlioblastomaSied Kebir (15048732)Vivien Ullrich (15048735)Pia Berger (15048738)Celia Dobersalske (15048741)Sarah Langer (15048744)Laurèl Rauschenbach (15048747)Daniel Trageser (15048750)Andreas Till (15048753)Franziska K. Lorbeer (15048756)Anja Wieland (15048759)Timo Wilhelm-Buchstab (15048762)Ashar Ahmad (15048765)Holger Fröhlich (8724576)Igor Cima (15048768)Shruthi Prasad (15048771)Johann Matschke (15048774)Verena Jendrossek (15048777)Marc Remke (14962619)Barbara M. Grüner (14947089)Alexander Roesch (15048780)Jens T. Siveke (11780911)Christel Herold-Mende (15047946)Tobias Blau (15048783)Kathy Keyvani (15048786)Frank K.H. van Landeghem (15048789)Torsten Pietsch (15048792)Jörg Felsberg (15048795)Guido Reifenberger (12335398)Michael Weller (15037908)Ulrich Sure (15048798)Oliver Brüstle (15048801)Matthias Simon (15048804)Martin Glas (15048807)Björn Scheffler (15048810)CancerTherapeutic Research and DevelopmentClinical Research and TrialsCNS CancersGliomas, GlioblastomasDrug TargetsPrecision Medicine<p>Extended Data relating to Main Figure 3/AKT-driven progression of ALDH1A1+ cells in glioblastoma. A, Flow cytometry histograms showing ALDH1A1 expression in the paired treatment-naive vs. clinical relapse patient samples quantified in main Fig. 3A. Isotype controls in gray. B, Flow cytometry histograms of ALDH1A1 derived from treatment-naive and paired experimental relapse (TMZ→eR) BN46 cells. Data quantification in Supplementary Fig. S2B. C, Cartoon illustrating course of neurosphere experiments, quantified in main Fig. 3B and in Supplementary Fig. S3D, applying treatment-naive and paired experimental and clinical relapse patient cells. Right: Exemplary qRT-PCR data presenting knockdown efficacy of the siRNA approach in respective cells, normalized to siNT control. Mean of duplicates ± SD. D, Source data for Fig. 3B, and for Supplementary Fig. S3E. Dotplots show percent neurosphere-forming cells estimated from neurospheres at 12 days after seeding. Paired patient cell analysis, evaluating 1° and 2° neurospheres of indicated knockdown (siALDH1A1) and respective control (siNT) cell samples. Data shown as mean ± SD. E, Neurosphere assay, similar to main Fig. 3B on paired treatment-naive vs. experimental relapse (TMZ→eR) BN46 cells. Source data in Supplementary Fig. S3D. Data as mean ± SD. F, Protein patterns, similar to Fig. 3D. on paired cells from 2 additional discovery cohort samples. G, Flow cytometry histograms depicting pAKT(Ser473) expression in the paired treatment-naive vs. clinical relapse patient samples quantified in main Fig. 3E. Isotype controls in gray. H, Flow cytometry histograms of pAKT(Ser473) and, right, quantification of data derived from treatment-naive and paired experimental relapse (TMZ→eR) BN46 cells. Data represent mean fluorescence intensities (MFI), ± SD, normalized to isotype control (gray). I, Representative source data for Fig. 3F. Flow cytometry profiles of ALDH1A1/pAKT(Ser473)-labeled, paired treatment-naive vs. clinical relapse cell samples. J, Flow cytometry profiles of of ALDH1A1/pAKT(Ser473)-labeled, paired treatment-naive vs. experimental relapse conditions of BN46 cells (in vitro exposure to TMZ (TMZ→eR) or irradiation (RT→eR)).</p>2025-11-25T12:46:36ZImageFigureinfo:eu-repo/semantics/publishedVersionimage10.1158/1078-0432.30706281https://figshare.com/articles/figure/Supplementary_Figure_S3_from_A_Sequential_Targeting_Strategy_Interrupts_AKT-Driven_Subclone-Mediated_Progression_in_Glioblastoma/30706281CC BYinfo:eu-repo/semantics/openAccessoai:figshare.com:article/307062812025-11-25T12:46:36Z |
| spellingShingle | Supplementary Figure S3 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma Sied Kebir (15048732) Cancer Therapeutic Research and Development Clinical Research and Trials CNS Cancers Gliomas, Glioblastomas Drug Targets Precision Medicine |
| status_str | publishedVersion |
| title | Supplementary Figure S3 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma |
| title_full | Supplementary Figure S3 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma |
| title_fullStr | Supplementary Figure S3 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma |
| title_full_unstemmed | Supplementary Figure S3 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma |
| title_short | Supplementary Figure S3 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma |
| title_sort | Supplementary Figure S3 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma |
| topic | Cancer Therapeutic Research and Development Clinical Research and Trials CNS Cancers Gliomas, Glioblastomas Drug Targets Precision Medicine |